ArticleBulletin of mathematical biology2026
Is Thymic Involution Truly a Deterioration or an Adaptation?
Article in Bulletin of mathematical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanism and intervention strategy of thymus atrophy in cancer immunotherapy.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In mammals, the immune system recognizes and combats pathogens while retaining a memory of prior encounters. In the thymus, naïve T cells capable of recognizing specific antigens are generated through random gene rearrangement, ensuring a diverse immune repertoire. However, the production rate of naïve T cells declines with age, typically following an exponential or power-law function-a phenomenon known as thymic involution, which is often regarded as a deterioration of biological function (immunosenescence). In this paper, we propose a novel theory suggesting that thymic involution may represent an adaptive strategy. As individuals age, repeated exposure to diverse pathogens leads to the accumulation of memory T cells, thereby reducing the need for newly generated naïve T cells to combat infections. Moreover, naïve T cells can persist in the periphery and retain the capacity to initiate immune responses against novel antigens. Using Pontryagin's Maximum Principle, we calculate the optimal schedule of naïve T cell production. The results show that the production rate peaks during a brief period shortly after birth, followed by an exponential decline throughout life, eventually reaching a phase in which naïve T cell production ceases. If peripheral naïve T cells decay very slowly, the optimal strategy may consist of producing all cohorts at birth, with no subsequent production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.